Cochrane · systematic review · CD012857
Extended‐release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
Boesen, K, Paludan-Müller, AS, Gøtzsche, PC, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 7 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Extended‐release methylphenidate compared to placebo for ADHD
Population: adults diagnosed with ADHD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Functional outcome:days missed at work/ school/ training Time of assessment: 13 weeks Extended‐release methylphenidate vs placebo | no estimate extracted | 1 study · 409 participants | Very low Downgraded: risk of bias, indirectness |
ADHD symptoms (self‐rated) Time of assessment: median 8 weeks (range 2 ‐ 26) Extended‐release methylphenidate vs placebo | no estimate extracted | 16 studies · 3799 participants | Very low Downgraded: risk of bias, indirectness |
Serious adverse events Time of assessment: median 8 weeks (range 4 ‐ 52) Extended‐release methylphenidate vs placebo | 1.43 [0.85, 2.43] | 14 studies · 4078 participants | Very low Downgraded: risk of bias, indirectness |
Quality of life (self‐rated) Time of assessment: median 6 weeks (range 4 ‐ 52) Extended‐release methylphenidate vs placebo | no estimate extracted | 6 studies · 1888 participants | Very low Downgraded: risk of bias, indirectness |
ADHD symptoms (investigator‐rated) Time of assessment: median 8 weeks (range 2 ‐ 26) Extended‐release methylphenidate vs placebo | no estimate extracted | 18 studies · 4183 participants | Very low Downgraded: risk of bias, indirectness |
ADHD symptoms (peer‐rated) Time of assessment: median 7.5 weeks (range 6 ‐ 9) Extended‐release methylphenidate vs placebo | no estimate extracted | 3 studies · 1005 participants | Very low Downgraded: risk of bias, indirectness |
Adverse events (proportion experiencing any adverse event) Time of assessment: median 8 weeks (range 4 ‐ 52) Extended‐release methylphenidate vs placebo | 1.27 [1.19, 1.37] | 14 studies · 4214 participants | Very low Downgraded: risk of bias, indirectness |